| Autor: |
Mistry, Goutam C., Majumdar, Anup K., Swan, Suzanne, Sica, Domenic, Fisher, Alison, Xu, Yang, Hesney, Michael, Xi, Liwen, Wagner, John, Deutsch, Paul |
| Zdroj: |
Journal of Clinical Pharmacology; Oct2006, Vol. 46 Issue 10, p1128-1138, 11p |
| Abstrakt: |
Ertapenem is a parenteral [.beta]-lactam carbapenem antibiotic. This open-label study examined the pharmacokinetics of single 1-g intravenous doses of ertapenem, administered over 30 minutes, in patients with mild, moderate,and advanced renal insufficiency (RI) and in patients with end-stage renal disease (ESRD) requiring hemodialysis. Pharmacokinetics were compared with historical controls pooled across healthy young and elderly subjects. Area under the concentration-time curve from time zero to infinity increased 7% in mild, 53% in moderate, 158% in advanced RI,and 192% in ESRD; end of infusion concentration changed minimally; half-life was 4.5 hours in the historical controlgroup and 4.4, 6.1, 10.6, and 14.1 hours in mild RI, moderate RI, advanced RI, and ESRD, respectively. Hemodialysis cleared[.similar]30% of the dose. The recommended dose in mild to moderate RI and after hemodialysis is unchanged at 1 g daily; and in advanced RI and ESRD is reduced to 0.5 g daily. If the daily dose is given 6 hours prior to hemodialysis, a supplementary 150-mg dose (30% of the daily dose) is recommended postdialysis. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text